

# Bowel Cancer Screening Programme Guideline for Patients with Liver Disease

Key Document code:	WAHT-KD-021		
Key Documents Owner:	Emma Duggan Bowel Cancer & Bowel Scope Screenin		
		Manager	
Approved by:	Endoscopy Governance Meeting		
Date of Approval:	4 <sup>th</sup> September 2024		
Date of review:	4 <sup>th</sup> September 2027		

Key Amendments			
Date Amendment Approved by			
September 24	New document	Endoscopy Governance	

#### INTRODUCTION

This operational guideline refers to all bowel cancer screening patients who have known Liver Disease

#### THIS GUIDELINE IS FOR USE BY THE FOLLOWING STAFF GROUPS :

This guideline applies to all staff working within the Herefordshire & Worcestershire BCSP team.

Guideline for patients with Liver Disease		
WAHT-KD-021	Page 1 of 7	Version 1

# Bowel Cancer Screening Programme WAHT-KD-021



#### Introduction

The aim of this guideline is to ensure the safety of patients with known Liver Disease who require a colonoscopy procedure.

#### Details Of Guideline

#### Prior to Procedure:

- Complete colonoscopy assessment using the Bowel Cancer Screening System.
- Establish patient has Liver Disease and if the patient is under a Gastroenterologist or Heptaologist.
- If the patient is under a Gastroenterologist or Hepatalogist obtain name and hospital.
- Ensure patient has an up to date Liver Function Blood Test (LFT) carried out at their General Practice Surgery (GP) or Hospital.
- In addition, INR or Prothrombin Time (PT) should be undertaken as denotes decompensation in cirrhosis and also increases the risk of procedure related bleeding.
- Review patient and results if significantly abnormal with Gastroenterologist or Hepatologist prior to proceeding with a Colonoscopy and taking Bowel Preparation.
- BCSP patients should not only be assessed for fitness to undergo the bowel preparation and colonoscopy but should also be assessed for fitness to correct complications should they arise i.e. laparotomy.
- Any concerns raised, discuss with Colonoscopist provisionally scheduled to do list.
- If the patient is not under a Gastroenterologist or Hepataologist and it is managed by GP no further action required.
- If the patient has high alcohol intake/alcoholism no LFT's required.

Guideline for patients with Liver Disease			
WAHT-KD-021Page 2 of 7Version 1			



Guideline for patients with Liver Disease			
WAHT-KD-021 Page 3 of 7		Version 1	



# Monitoring Tool

Page/	Key control:	Checks to be carried out to confirm	How often the	Responsible	Results of check reported	Frequency of
Section of		compliance with the policy:	check will be	for carrying	to:	reporting:
Key			carried out:	out the	(Responsible for also	
Document				check:	ensuring actions are	
					developed to address any	
					areas of non-compliance)	
	WHAT?	HOW?	WHEN?	WHO?	WHERE?	WHEN?
	BCSS database	Review patient data on BCSS to	Post clinic review,	SSP	Appropriate SSP	Not discussed
		ensure Liver disease accurately	pre-procedure			
		recorded.				

Guideline for patients with Liver Disease		
WAHT-KD-021 Page 4 of 7		Version 1



#### **Contribution List**

This key document has been circulated to the following individuals for consultation;

Designation
BCSP Screening Director
BCSP Matron
Lead SSP
SSPs

This key document has been circulated to the chair(s) of the following committee's / groups for comments;

Committee		
BCSP Operational Group		
Endoscopy Directorate Meeting		

## **Supporting Document 1 - Equality Impact Assessment Tool**

Guideline for patients with Liver Disease		
WAHT-KD-021	Page 5 of 7	Version 1



To be completed by the key document author and attached to key **NHS** document when submitted to the appropriate committee for consideration and approval.

		Yes/No	Comments
1.	Does the policy/guidance affect one group less or more favourably than another on the basis of:		
	Race	No	
	Ethnic origins (including gypsies and travellers)	No	
	Nationality	No	
	Gender	No	
	Culture	No	
	Religion or belief	No	
	Sexual orientation including lesbian, gay and bisexual people	No	
	Age	No	
2.	Is there any evidence that some groups are affected differently?	No	
3.	If you have identified potential discrimination, are any exceptions valid, legal and/or justifiable?	N/A	
4.	Is the impact of the policy/guidance likely to be negative?	No	
5.	If so can the impact be avoided?	N/A	
6.	What alternatives are there to achieving the policy/guidance without the impact?	None	
7.	Can we reduce the impact by taking different action?	No	

If you have identified a potential discriminatory impact of this key document, please refer it to Human Resources, together with any suggestions as to the action required to avoid/reduce this impact.

For advice in

Guideline for patients with Liver Disease		
WAHT-KD-021	Page 6 of 7	Version 1

### Bowel Cancer Screening Programme WAHT-KD-021



## Supporting Document 2 – Financial Impact Assessment

To be completed by the key document author and attached to key document when submitted to the appropriate committee for consideration and approval.

	Title of document:	Yes/No
1.	Does the implementation of this document require any additional Capital resources	No
2.	Does the implementation of this document require additional No	
3.	Does the implementation of this document require additional manpower	No
4.	Does the implementation of this document release any manpower costs through a change in practice	No
5.	Are there additional staff training costs associated with implementing this document which cannot be delivered through current training programmes or allocated training times for staff	No
	Other comments:	None

If the response to any of the above is yes, please complete a business case and which is signed by your Finance Manager and Directorate Manager for consideration by the Accountable Director before progressing to the relevant committee for approval.

Guideline for patients with Liver Disease			
WAHT-KD-021	Page 7 of 7	Version 1	